Research Database

To determine the prevalence and breakdown of KRAS mutations, co-occurring oncogenic mutations, and PD-L1 expression in a large UK cohort of non-small cell lung...

This study investigates the frequency and type of K-ras gene mutations at codons 12, 13, and 61 in human pancreatic cancer cell lines and bile samples from...

This study aims to assess the prevalence of STK11, KEAP1, and KRAS mutations and their co-mutations in metastatic non-small cell lung cancer (mNSCLC) patients...

This study investigates whether overexpression of wild-type RRAS2, without activating mutations, drives triple-negative breast cancer (TNBC), particularly in...

The study investigates the prevalence and co-occurrence patterns of RAS mutations across 51 cancer types using genomic data from 66,372 tumors to identify...

This review examines the molecular signaling pathways—KRAS, TP53-MDM2, EGFR, and PI3K/AKT/mTOR—that drive pancreatic ductal adenocarcinoma (PDAC) and their...

To evaluate whether daraxonrasib improves survival compared to chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma...

To evaluate the safety, efficacy, and early ctDNA reduction of RMC-6236 in patients with previously treated RAS mutant pancreatic ductal adenocarcinoma (PDAC).

Why oncogenic KRAS mutations alone are insufficient to cause full cancer transformation.